Haemonetics (HAE) to Release Quarterly Earnings on Thursday

Haemonetics (NYSE:HAE) is projected to release its Q3 2026 results before the market opens on Thursday, February 5th. Analysts expect the company to announce earnings of $1.27 per share and revenue of $331.8980 million for the quarter. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Investors are encouraged to explore the company’s upcoming Q3 2026 earning overview page for the latest details on the call scheduled for Thursday, February 5, 2026 at 8:00 AM ET.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.15. The business had revenue of $327.32 million during the quarter, compared to analysts’ expectations of $311.61 million. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.The company’s revenue was down 5.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.12 EPS. On average, analysts expect Haemonetics to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Haemonetics Trading Down 2.6%

Shares of HAE stock opened at $66.10 on Thursday. Haemonetics has a 1-year low of $47.31 and a 1-year high of $87.32. The firm has a market cap of $3.09 billion, a PE ratio of 19.33, a price-to-earnings-growth ratio of 1.41 and a beta of 0.29. The company has a 50-day moving average of $78.90 and a two-hundred day moving average of $65.57. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC grew its position in shares of Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 396 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in Haemonetics by 20,925.0% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 841 shares of the medical instruments supplier’s stock worth $41,000 after purchasing an additional 837 shares during the period. CIBC Private Wealth Group LLC boosted its stake in Haemonetics by 69.3% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,094 shares of the medical instruments supplier’s stock worth $53,000 after purchasing an additional 448 shares during the period. Quadrant Capital Group LLC purchased a new position in Haemonetics during the 3rd quarter worth $76,000. Finally, Strs Ohio acquired a new position in Haemonetics in the first quarter valued at $140,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on HAE shares. Needham & Company LLC lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Monday, December 15th. Robert W. Baird raised their price target on shares of Haemonetics from $87.00 to $99.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. Mizuho upped their price objective on Haemonetics from $75.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. BTIG Research reiterated a “buy” rating and issued a $88.00 price objective on shares of Haemonetics in a research note on Friday, January 9th. Finally, Citigroup lowered their target price on Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a research note on Tuesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $84.40.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.